TABLE 2.
Subgroup analysis details.
| Subgroup | (OR, 95% CI) | Number of studies | Number of patients | p | Heterogeneity | ||||
|---|---|---|---|---|---|---|---|---|---|
| Tau2 | Chi2 | df | I 2 (%) | p | |||||
| Cancer type | |||||||||
| Breast cancer | 3.93 (1.76, 8.78) | 9 | 454 | <0.001 | 0.48 | 11.27 | 17 | 57 | 0.001 |
| Rectal cancer | 2.53 (1.05, 6.10) | 14 | 661 | 0.04 | 1.64 | 32.65 | 13 | 60 | 0.002 |
| Digestive tract cancer | 3.51 (1.65, 7.57) | 18 | 777 | 0.001 | 1.43 | 39.69 | 3 | 0 | 0.56 |
| Time points | |||||||||
| Pre‐NAT | 1.58 (0.80, 3.12) | 11 | 464 | 0.19 | 0.38 | 13.28 | 9 | 32 | 0.15 |
| Post‐NAT | 4.26 (1.81, 9.98) | 13 | 609 | <0.001 | 1.41 | 31.27 | 12 | 62 | 0.002 |
| Post‐surgery | 14.55 (6.87, 30.82) | 15 | 629 | <0.001 | 0.72 | 21.21 | 14 | 34 | 0.10 |
| Area | |||||||||
| America | 3.26 (1.46, 7.30) | 13 | 564 | 0.004 | 1.08 | 26.58 | 12 | 55 | 0.009 |
| Asia | 4.42 (1.70, 11.49) | 13 | 589 | 0.002 | 1.52 | 24.58 | 11 | 55 | 0.01 |
| Europe | 8.91 (2.89, 27.47) | 10 | 410 | <0.001 | 2.11 | 27.05 | 9 | 67 | 0.001 |
| Australia | 6.50 (1.40, 30.12) | 4 | 174 | 0.02 | 1.64 | 9.32 | 3 | 68 | 0.03 |
Abbreviations: CI, confidential interval; OR, odds ratio; NAT, neoadjuvant treatment.